Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > BUSINESS
BUSINESS
- Santen to Create New Exec Posts to Accelerate Globalization
March 13, 2014
- Novartis Japan Sales Tick Up 0.8%, Diovan Down 13%, Tasigna Up 35%
March 13, 2014
- Torii Confirms Positive Results from PII/III Study of Investigational Allergen Immunotherapy Treatment TO-203
March 13, 2014
- AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
- 19 Pharmacy-Operating Companies Join Bidding Group for Drug Purchasing
March 12, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
March 12, 2014
- Eisai to Forge Cross-Regional Biz Units for Oncology, Neurology in July
March 11, 2014
- Otsuka, UCB Japan File Partial Change Application for Monotherapy for E Keppra
March 11, 2014
- Ethical Drug Sales Up 4.7% in January Owing to Growth in Influenza-Related Products: Crecon Report
March 11, 2014
- Takeda Picks Third-Party Investigator for CASE-J Issue, Probe Expected to Take 3 Months
March 11, 2014
- Pfizer Japan Logs 1.2% Sales Increase in FY2013
March 10, 2014
- Eisai, Biogen Idec to Jointly Develop, Commercialize AD Treatments
March 10, 2014
- Asahi Kasei Pharma Exec Hori Picked as Next President
March 10, 2014
- Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
- US Journal to Revise COI Disclosure in Article Used by Shionogi and Eli Lilly Japan to Promote Cymbalta
March 10, 2014
- 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
- Map Software Used to Reorganize MRs’ Marketing Territories Boosts Operating Efficiency at Pfizer Japan
March 7, 2014
- Five Generic Makers See Various Price Reduction Rates under FY2014 NHI Revision
March 6, 2014
- New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
- Santen Licenses Anti-Endoglin Antibodies from TRACON to Develop Novel Treatments for Retinal Diseases
March 6, 2014
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…